FFA
AVBP icon

Farther Finance Advisors’s ArriVent BioPharma AVBP Stock Holding History

Farther Finance Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.7K Sell
631
-40
-6% -$1.18K ﹤0.01% 3911
2026
Q1 		$16.3K Buy
671
+336
+100% +$7.59K ﹤0.01% 3793
2025
Q4 		$6.74K Buy
+335
New +$6.97K ﹤0.01% 4157

Other funds holding AVBP

TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Farther Finance Advisors's AVBP Position: Q2 2026 in Review

Farther Finance Advisors reduced its ArriVent BioPharma (AVBP) stake by 6% in Q2 2026, selling an estimated $1.18K and leaving 631 shares worth $21.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3911.

Farther Finance Advisors first reported a position in AVBP in Q4 2025 and has held it in 3 quarters since. 10 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Farther Finance Advisors held 631 shares of ArriVent BioPharma worth $21.7K as of Q2 2026.
  • Farther Finance Advisors sold 40 ArriVent BioPharma shares in Q2 2026, an estimated $1.18K.
  • ArriVent BioPharma made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #3911 holding.
  • Farther Finance Advisors first reported a position in ArriVent BioPharma in Q4 2025 and has held it in 3 quarters since.
  • 10 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.